- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- IcoSema, Insulin icodec
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 110
- States / cities
- Gilbert, Arizona • Glendale, Arizona • Phoenix, Arizona + 90 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Type 2 Diabetes, Insulin Treated Type 2 Diabetes Mellitus
- Interventions
- twiist insulin delivery system
- Device
- Lead sponsor
- Deka Research and Development
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 30
- States / cities
- La Jolla, California • Newport Beach, California • Santa Barbara, California + 24 more
- Conditions
- Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
- Interventions
- Exenatide
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Diabetes
- Interventions
- Dexcom G6 CGM - Continues Glucose Monitoring sensor system, POC BG - Point-of-Care Blood Glucose monitoring
- Device · Diagnostic Test
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- AC2993, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 126
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 99 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- BI 10773 placebo, BI 10773 low dose, BI 10773 high dose
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 494 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 50 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 1
- Interventions
- insulin degludec/insulin aspart, insulin detemir, insulin aspart
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 548 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 30
- States / cities
- La Mesa, California • Lancaster, California • Mission Hills, California + 25 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- insulin degludec/liraglutide, insulin degludec, liraglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,663 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 146
- States / cities
- Birmingham, Alabama • Anaheim, California • Bermuda Dunes, California + 126 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Glooko's mobile application
- Device
- Lead sponsor
- Glooko
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 4
- States / cities
- Concord, California • Elk Grove, California • San Diego, California + 1 more
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Interventions
- Afrezza, Rapid-acting Insulin Analog, Basal Insulin
- Biological
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 319 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 39
- States / cities
- Los Angeles, California • Orange, California • Palo Alto, California + 35 more
- Conditions
- Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
- Interventions
- Basal Insulin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- insulin degludec/insulin aspart
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 28
- States / cities
- Goodyear, Arizona • Anaheim, California • Greenbrae, California + 24 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin Peglispro, Insulin Glargine, Insulin Lispro
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- semaglutide, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 731 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 50
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Fountain Hills, Arizona + 44 more
- Conditions
- Type 2 Diabetes
- Interventions
- Insulin glargine/lixisenatide Fixed Ratio Combination, Insulin glargine (HOE901), Lixisenatide (AVE0010), Metformin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 118
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Little Rock, Arkansas + 98 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- IcoSema, Semaglutide 1 mg
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 683 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Sun City West, Arizona + 41 more
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Positive Airway Pressure therapy, Lifestyle counseling
- Device · Behavioral
- Lead sponsor
- ResMed
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 11
- States / cities
- Mission Viejo, California • Temecula, California • Coral Gables, Florida + 8 more
- Conditions
- Metabolism and Nutrition Disorder, Obesity
- Interventions
- Liraglutide 3.0 mg, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 396 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Concord, California • Fresno, California + 14 more
- Conditions
- Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
- Interventions
- Canakinumab 150 mg, Placebo to Canakinumab
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- insulin degludec, insulin aspart, liraglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 413 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 48
- States / cities
- Concord, California • La Jolla, California • Lancaster, California + 44 more
- Conditions
- Type 2 Diabetes Treated With Insulin
- Interventions
- Afrezza Inhalant Product
- Drug
- Lead sponsor
- Diabetes and Glandular Disease Clinic
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Canagliflozin, 100 mg, Canagliflozin, 300 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 25 Years to 70 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- San Diego, La Jolla, California • Gainesville, Florida
- Conditions
- Type 2 Diabetes, Hyperglycemia
- Interventions
- sliding scale regular insulin (SSRI), Basal Bolus, Basal Plus
- Drug
- Lead sponsor
- Guillermo Umpierrez, MD
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Decatur, Georgia • Charleston, South Carolina + 1 more
- Conditions
- Type 2 Diabetes
- Interventions
- Cagrilintide, Semaglutide, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 14
- States / cities
- Northridge, California • Miami, Florida • Meridian, Idaho + 10 more